CN113164548A - 用于治疗糖尿病的肽片段 - Google Patents

用于治疗糖尿病的肽片段 Download PDF

Info

Publication number
CN113164548A
CN113164548A CN201980081421.2A CN201980081421A CN113164548A CN 113164548 A CN113164548 A CN 113164548A CN 201980081421 A CN201980081421 A CN 201980081421A CN 113164548 A CN113164548 A CN 113164548A
Authority
CN
China
Prior art keywords
peptide
seq
agent
amino acid
fol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980081421.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·阿伦法尔
M·埃克布拉德
P·杜纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Follicum AB
Original Assignee
Follicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum AB filed Critical Follicum AB
Publication of CN113164548A publication Critical patent/CN113164548A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980081421.2A 2018-11-07 2019-11-07 用于治疗糖尿病的肽片段 Pending CN113164548A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
EP18204862.9 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
CN113164548A true CN113164548A (zh) 2021-07-23

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081421.2A Pending CN113164548A (zh) 2018-11-07 2019-11-07 用于治疗糖尿病的肽片段

Country Status (13)

Country Link
US (2) US20220002343A1 (https=)
EP (1) EP3876970A1 (https=)
JP (1) JP7553115B2 (https=)
KR (1) KR20210088583A (https=)
CN (1) CN113164548A (https=)
AU (1) AU2019374981A1 (https=)
BR (1) BR112021008888A2 (https=)
CA (1) CA3116612A1 (https=)
IL (1) IL282519A (https=)
MX (1) MX2021005386A (https=)
SG (1) SG11202104276YA (https=)
WO (1) WO2020094797A1 (https=)
ZA (1) ZA202102572B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
JP2025516717A (ja) * 2022-05-13 2025-05-30 コーギン ファーマ エービー 血管新生を誘発する薬剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN1683408A (zh) * 2004-04-14 2005-10-19 贝达医药开发(上海)有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
CN103930125A (zh) * 2011-08-10 2014-07-16 富力卡姆股份公司 具有失活rgd域的修饰的骨桥蛋白肽及其用途
US20140221278A1 (en) * 2005-06-17 2014-08-07 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
CN106413734A (zh) * 2014-04-17 2017-02-15 富力卡姆股份公司 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物
WO2018202870A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505750A (ja) * 1994-09-16 1998-06-09 ザ スクリップス リサーチ インスティテュート 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN1683408A (zh) * 2004-04-14 2005-10-19 贝达医药开发(上海)有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
US20140221278A1 (en) * 2005-06-17 2014-08-07 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
CN103930125A (zh) * 2011-08-10 2014-07-16 富力卡姆股份公司 具有失活rgd域的修饰的骨桥蛋白肽及其用途
CN106413734A (zh) * 2014-04-17 2017-02-15 富力卡姆股份公司 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物
WO2018202870A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BETTEGOWDA CHETAN: "The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT", 《NATURE BIOTECHNOLOGY》, vol. 24, no. 12, 19 December 2006 (2006-12-19), pages 1573 - 1580, XP055295750, DOI: 10.1038/nbt1256 *
TAKESHI KINOSHITA: "Distinct Glycosylation in Interstitial and Serum Tenascin-X", 《BIOLOGICAL AND PHARMACEUTICAL BULLETIN》, vol. 30, no. 2, 14 October 2007 (2007-10-14), pages 354 - 358 *

Also Published As

Publication number Publication date
AU2019374981A1 (en) 2021-05-27
SG11202104276YA (en) 2021-05-28
BR112021008888A2 (pt) 2021-08-17
KR20210088583A (ko) 2021-07-14
ZA202102572B (en) 2022-10-26
US20240327459A1 (en) 2024-10-03
CA3116612A1 (en) 2020-05-14
IL282519A (en) 2021-06-30
US20220002343A1 (en) 2022-01-06
WO2020094797A1 (en) 2020-05-14
JP2022516400A (ja) 2022-02-28
EP3876970A1 (en) 2021-09-15
MX2021005386A (es) 2021-07-06
JP7553115B2 (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
JP4496183B2 (ja) グルカゴン様ペプチド−２、ならびにその治療への使用
US7186694B2 (en) Leptin-related peptides
Gutkowska et al. Structure, expression, and function of atrial natriuretic factor in extraatrial tissues
CN110545834B (zh) 用于治疗糖尿病的肽
JPH05506427A (ja) 糖尿病治療に有用なｇｌｐ―１アナログ
JPH04507240A (ja) インシュリン様成長因子及び類似体を用いる障害治療方法
CA2266416C (en) Insulin c-peptides
US7208572B2 (en) Leptin-related peptides
US20240327459A1 (en) Peptide fragments for treatment of diabetes
Dockray et al. Vertebrate brain-gut peptides related to FMRFamide and Met-enkephalin Arg6Phe7
Daugherty et al. Posttranslational processing of gastrin
Stridsberg et al. Islet amyloid polypeptide (IAPP) a short review
HK40017988A (en) Peptides for treatment of diabetes
Wagner et al. The stimulatory effect of amylin on mucus secretion in isolated rat trachea
CN101128213B (zh) 胰腺β细胞再生的促进剂以及在胰腺β细胞中生产胰岛素的促进剂
Bryant et al. Design and characterisation of long-R3-insulin-like growth factor-I muteins which show resistance to pepsin digestion
PAOLINI Research & Development of chimeric peptides involved in the hypothalamic-pituitary axis to optimise their cell proliferation regulatory activity in different disease conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723